MetaVia Announces the Pricing of $8.1 Million Underwritten Public Offering

Core Viewpoint - MetaVia Inc. has announced the pricing of its underwritten public offering, aiming to raise approximately $8.1 million before expenses and potential future proceeds from warrant exercises [1] Company Summary - MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases [1] - The offering includes shares of common stock, Series C Warrants, and Series D Warrants [1] Financial Summary - The gross proceeds from the public offering are approximately $8.1 million, excluding underwriting discounts, commissions, and offering expenses [1]